(+/-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
- Item No. 2022033191003MOQ 1 Kilogram
Choice

If you have your own design, please contact us, there will have a professional customer service to communicate with you.
Don't have your files right now?No worries, Check out our art tips for more information.
If over 500pcs, mass production will start until pre-production sample has been approved.
Est. 7 days production
Cilnidipine is a calcium channel blocker. It is sold as 'Atelec' in Japan, and as 'Cilacar' in India as 5 mg and 10 mg tablets. Cilnidipine is a dual blocker of L-type voltage-gated calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals that supply blood vessels. However, the clinical benefits of cilnidipine and underlying mechanisms are incompletely understood. Clinidipine is the new type of calcium antagonist accompanied with L-type and N-type calcium channel blocking function. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved to come into market for the first time and used for high blood pressure treatment in 1995. Compared with other calcium antagonists, clinidipine can act on the N-type calcium-channel that existing sympathetic nerve end besides acting on L-type calcium-channel that similar to most of the calcium antagonists.

Business Type | Manufacturer, Trading Company | Country / Region | Jiangsu, China |
Main Products | SARS CoV2 S1 Protein,SARS CoV2 RBD Protein,CRISPR-Cas Enzymes(LbuCas12a,AacCas12b,LwaCas13a),Cytokines(PDGF,BFGF) | Total Employees | 11 - 50 People |
Total Annual Revenue | 5938782 USD | Year Established | 2016 |
Certifications | ISO9001 | Product Certifications | |
Patents | Trademarks | ||
Main Markets | Domestic Market 100% |
Send your message to us
No need register, just fill in contact info below, we will reply you within 24 hours!